Physician profile
Allison Brochtrup
NPI 1104405992
$2,245.33
in general payments reported to CMS, 2019-2025
19 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $370 · 2023: $375 · 2024: $800 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.47 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $260.44 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $249.18 | 2022-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $241.81 | 2022-2023 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $239.87 | 2023-2025 | Camzyos, Eliquis, Cobenfy |
| Novo Nordisk INC | $231.61 | 2023-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $199.86 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $161.80 | 2024-2025 | Onpattro |
| Pfizer INC. | $121.00 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $108.78 | 2023-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $96.59 | 2022-2025 | |
| Abbott Laboratories | $86.71 | 2023-2025 | Cardiomems |
| Amgen INC. | $80.76 | 2023-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $40.98 | 2024 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $32.93 | 2024 | Arcalyst |
| Cvrx, INC. | $21.72 | 2024 | Barostim Neo System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $20.56 | 2023 | Treprostinil |
| Scpharmaceuticals INC. | $18.56 | 2024 | |
| Medtronic, INC. | $16.49 | 2024 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.68 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Brochtrup listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.